LYNNETTE AVERILL to Depressive Disorder, Major
This is a "connection" page, showing publications LYNNETTE AVERILL has written about Depressive Disorder, Major.
Connection Strength
2.866
-
Functional connectome-based predictive modeling of suicidal ideation. J Affect Disord. 2025 Oct 15; 387:119518.
Score: 0.670
-
mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. J Affect Disord. 2022 04 15; 303:91-97.
Score: 0.532
-
Early life stress and glutamate neurotransmission in major depressive disorder. Eur Neuropsychopharmacol. 2020 06; 35:71-80.
Score: 0.473
-
Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence. Adv Pharmacol. 2020; 89:163-194.
Score: 0.473
-
Medial prefrontal cortex neurotransmitter abnormalities in posttraumatic stress disorder with and without comorbidity to major depression. NMR Biomed. 2024 Nov; 37(11):e5220.
Score: 0.158
-
Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023 01 15; 321:140-146.
Score: 0.140
-
A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants. Neuropsychopharmacology. 2021 01; 46(2):478-485.
Score: 0.121
-
Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology. 2020 05; 45(6):990-997.
Score: 0.116
-
Ketamine Treatment and Global Brain Connectivity in Major Depression. Neuropsychopharmacology. 2017 May; 42(6):1210-1219.
Score: 0.092
-
Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. Hum Brain Mapp. 2016 09; 37(9):3214-23.
Score: 0.089